July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A LEADING LAW FIRM, Encourages Shattuck Labs, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm – STTK
March 12, 2022 13:18 ET | The Rosen Law Firm PA
NEW YORK, March 12, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Shattuck Labs, Inc. (NASDAQ: STTK): (i) pursuant and/or...
July 30, 2021 - ROSEN LOGO.jpg
STTK SHAREHOLDER ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Shattuck Labs, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm – STTK
March 07, 2022 14:01 ET | The Rosen Law Firm PA
NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Shattuck Labs, Inc. (NASDAQ: STTK): (i) pursuant and/or...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Shattuck Labs, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm – STTK
February 20, 2022 16:30 ET | The Rosen Law Firm PA
NEW YORK, Feb. 20, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Shattuck Labs, Inc. (NASDAQ: STTK): (i) pursuant and/or...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Shattuck Labs, Inc. Investors With Losses Over $100K to Secure Counsel Before Important April 1 Deadline in Securities Class Action Commenced by the Firm – STTK
February 05, 2022 11:52 ET | The Rosen Law Firm PA
NEW YORK, Feb. 05, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Shattuck Labs, Inc. (NASDAQ: STTK): (i) pursuant and/or...
July 30, 2021 - ROSEN LOGO.jpg
STTK INVESTOR NEWS: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Shattuck Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm – STTK
February 01, 2022 09:45 ET | The Rosen Law Firm PA
NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of...
Logo.png
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline: Insights into New Pipeline Therapies and Landscape; Future Key Pharma Companies and Novel Therapeutic Assessment
August 12, 2021 20:00 ET | DelveInsight Business Research LLP
Los Angeles, USA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Alpha-1 Antitrypsin Deficiency Liver Disease Pipeline: Insights into New Pipeline Therapies and Landscape; Future Key Pharma Companies and Novel...
CENTOGENElogo.jpg
CENTOGENE Extends Partnership With Takeda
April 14, 2021 06:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, April 14, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
logo-alt.png
Global Diabetes Drugs Market–Analysis and Demand with Forecast Overview to 2029 - by PMI
January 12, 2021 10:05 ET | PMI
Covina, CA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The significant growth in the market can be attributed to factors, such as the rising prevalence of diabetes and the increasing number of programs...
Light Chain Bioscience successfully completes Factor VIII mimetic bispecific antibody discovery for Takeda
February 14, 2020 03:00 ET | Light Chain Bioscience - NovImmune SA
GENEVA, Switzerland, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Light Chain Bioscience, a company developing bispecific antibodies with a pipeline focused in immuno-oncology, announced that it has achieved a...
LogicBio-logo-RGB.png
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
January 10, 2020 07:05 ET | LogicBio Therapeutics
– Filed IND for lead GeneRide™ candidate LB-001 in pediatric MMA patients –– Phase 1/2 trial initiation planned for H1 2020, with preliminary data in H2 2020 –– Established research collaboration with...